H.C. Wainwright analyst Emily Bodnar has maintained their bullish stance on AGIO stock, giving a Buy rating on July 28.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Emily Bodnar’s rating is based on Agios Pharma’s strategic preparations for the upcoming launch of mitapivat (Pyrukynd) for thalassemia, with a PDUFA date set for September 7. The company has reported no disruptions in their interactions with the FDA, and the labeling discussions are progressing without changes to the safety profile. Agios has expanded its sales and marketing team to support the launch, focusing on specific patient groups and leveraging established relationships with key opinion leaders and advocacy groups. Additionally, Agios is expanding its reach internationally, with regulatory applications submitted in the EU, Kingdom of Saudi Arabia, and UAE, and partnerships in place to support these markets. The company’s efforts to educate on non-transfusion dependent thalassemia, a segment with no approved therapies, further strengthen its market position. Furthermore, the promising Phase 2 data from the RISE UP study for sickle cell disease (SCD) suggests strong potential for mitapivat, enhancing its prospects for future growth.
According to TipRanks, Bodnar is an analyst with an average return of -1.9% and a 31.13% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Agenus, Agios Pharma, and NovoCure.
In another report released on July 28, Scotiabank also maintained a Buy rating on the stock with a $65.00 price target.